QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

22,491 signal articles · 108 in last 24h · 107,910 total before filter · latest 39m ago
108last 24h
2582last 7d
488● bullish (7d)
238● bearish (7d)
202publishers
AllMacro222Earnings1613M&A119Regulatory16Product10Analyst25
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Vicor (VICR) Stock Looks Pricey On Cash Flow Yet Cheap On Earnings
Simply Wall St.9d agoneutral
Vicor (VICR) Stock Looks Pricey On Cash Flow Yet Cheap On Earnings

Vicor has delivered a very large 371.4% return over the past year, yet its valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a premium while market based multiples still screen as relatively undemanding. Over the last 12 months, Vicor shares are up 371.4%, which puts a lot more focus on whether the current price leaves enough room for error. Future growth in cash flows from Vicor's power solutions can support the current share...

Mastercard Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Mastercard Q2 Earnings Call Highlights

Mastercard (NYSE:MA) reported second-quarter 2026 results that exceeded its expectations, supported by continued consumer and business spending, cross-border activity and demand for its value-added services. On a non-GAAP, currency-neutral basis, net revenue rose 12% year over year, adjusted net in

Private credit roundup: Earnings hold up as defaults, redemptions remain elevated
Reuters9d agoneutral
Private credit roundup: Earnings hold up as defaults, redemptions remain elevated

Ares Capital and Blue Owl Capital reported resilient second-quarter results this week, while Ares Management posted record fundraising, highlighting continued institutional demand for private credit despite rising defaults, ‌retail redemptions and liquidity concerns. Ares Management, one of the industry's largest players, raised a record $36 billion ‌in the second quarter, including $23.7 billion for its credit strategies. Assets under management rose 17% from a year earlier to $671.3 billion.

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.
Barrons.com9d agobullish
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.